Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial is expected to recruit patients with primary Parkinson's disease and give them four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism
This trial is expected to recruit patients with primary Parkinson's disease who are distributed into tremor group and stiff group and give them the same kind of four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tremor group | Active Comparator | Participants in the tremor group have tremor as the main clinical manifestation |
|
| Stiff group | Active Comparator | Participants in the tremor group have stiff as the main clinical manifestation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| aerobic exercise | Behavioral | Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Movement Disorder Society-United Parkinson's Disease Rating Scale (MDS-UPDRS) | to assess the motor and nonmotor function of PD,0-200 scores,the higher scores mean lower function | changes of MDS-UPDRS score from baseline at four weeks |
| Montreal Cognitive Assessing(MoCA) score | to assess the cognitive function of PD,0-30 scores,the higher scores mean better function | changes of MoCA score from baseline at four weeks |
| The Epworth Sleeping Scale(ESS) | to assess the degree of drowsiness, 0-24 scores, the higher scores mean severe drowsiness | changes of ESS score from baseline at four weeks |
| Non-Motor Symptom Scale (NMSS) | to assess the non-motor of PD , 0-120 scores, the higher scores mean severe non-motor damage | changes of NMSS score from baseline at four weeks |
| Measure | Description | Time Frame |
|---|---|---|
| cerebral blood variation by Head MRI | to assess the cerebral blood variation by head MRI | changes of the cerebral blood from baseline at four weeks |
| cerebral blood flow velocity | cerebral blood flow velocity is recorded using transcranial Doppler and a servo-controlled plethysmograph respectively. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ying Zhang, Doctor | The First Hospital of Jilin University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| FirstJilinU | Changchun | 130021 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| changes of the cerebral blood flow velocity from baseline at four weeks |
| the level of arterial blood pressure | arterial blood pressure is recorded using transcranial Doppler and a servo-controlled plethysmograph respectively. Both systolic and diastolic pressures will be assessed during the study period. | changes of the arterial blood pressure from baseline at four weeks |
| the concentration of microRNA in peripheral blood by gene chip | to test the the concentration of microRNA in peripheral blood | changes of microRNA from baseline at four weeks |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D001519 | Behavior |